| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 53.168 | 50.666 | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 53.168 | 52.581 | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 64.712 | 47.566 | - | - | - | 0 | 0 | 0 | 0 | 2.288 |
| Gross Profit/Loss - EUR | -11.545 | 5.015 | - | - | - | 0 | 0 | 0 | 0 | -2.288 |
| Net Profit/Loss - EUR | -13.140 | 4.509 | - | - | - | 0 | 0 | 0 | 0 | -2.288 |
| Employees | 4 | 3 | - | - | - | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Ghedocrin Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 15.065 | 14.855 | - | - | - | 13.792 | 13.486 | 13.528 | 13.487 | 13.411 |
| Current Assets | 5.507 | 7.220 | - | - | - | 6.324 | 6.184 | 6.203 | 12.026 | 2.298 |
| Inventories | 529 | 877 | - | - | - | 697 | 682 | 684 | 992 | 1.167 |
| Receivables | 4.707 | 5.781 | - | - | - | 5.391 | 5.271 | 5.288 | 965 | 965 |
| Cash | 271 | 561 | - | - | - | 236 | 231 | 231 | 10.070 | 166 |
| Shareholders Funds | -141.335 | -135.385 | - | - | - | -121.342 | -118.651 | -119.019 | -174.502 | -175.815 |
| Social Capital | 70 | 69 | - | - | - | 64 | 63 | 63 | 63 | 62 |
| Debts | 161.906 | 157.459 | - | - | - | 141.458 | 138.321 | 138.750 | 200.016 | 191.525 |
| Income in Advance | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5610 - 5610" | |||||||||
| CAEN Financial Year |
5520
|
|||||||||
Comments - Ghedocrin Srl